XML 39 R22.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Business Segment Information | 12 Months Ended
--- | ---
Dec. 31, 2017
Segment Reporting [Abstract] |
Business Segment Information | Business Segment Information Our Medical Devices operating segment, which is also our reportable global business segment, was determined in accordance with how our executive managers currently develop and execute global strategies to drive growth and profitability. The Medical Devices segment provides a portfolio of innovative product offerings focused on pain management and respiratory and digestive health to improve patient outcomes and reduce the cost of care. These products include post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems and enteral feeding tubes. Information concerning operations of our business segment is presented in the following table (in millions):
| Year Ended December 31,
| 2017 |  | 2016 |  | 2015
Net Sales |  |  |  |  |
Medical Devices | $ | 611.6 |  |  | $ | 566.2 |  |  | $ | 509.0 |
Corporate and Other | — |  |  | — |  |  | — |
Total Net Sales | 611.6 |  |  | 566.2 |  |  | 509.0 |
Operating Profit (Loss) |  |  |  |  |
Medical Devices | 155.2 |  |  | 123.8 |  |  | 107.8 |
Corporate and Other(a)(b)(c) | (178.2 | ) |  | (211.2 | ) |  | (227.3 | )
Other (expense) income, net(d) | (20.1 | ) |  | (19.7 | ) |  | (16.2 | )
Total Operating Loss | (43.1 | ) |  | (107.1 | ) |  | (135.7 | )
Interest income | 2.5 |  |  | 0.6 |  |  | 0.3 |
Interest expense | (31.6 | ) |  | (32.7 | ) |  | (33.1 | )
Loss before Income Taxes | $ | (72.2 | ) |  | $ | (139.2 | ) |  | $ | (168.5 | )
_______________________________________________
(a) | For the year ended December 31, 2017, Corporate and other costs included $116 million, respectively, of costs historically presented as a component of the S&IP business, $55 million of general expenses, $5 million of restructuring costs and $8 million of acquisition-related charges partially offset by a $6 million benefit related to realignment of internal policies for our post-divestiture business.
(b) | For the year ended December 31, 2016, Corporate and other costs included $114 million of costs historically presented as a component of the S&IP business, $66 million of general expenses, $14 million of post spin-related costs $18 million, respectively, of acquisition-related charges.
(c) | For the year ended December 31, 2015, Corporate and other costs included $133 million of costs historically presented as a component of the S&IP business, $49 million of general expenses and $46 million of post spin-related expenses.
(d) | Other expense, net is primarily costs related to litigation and legal matters.
For the year ended December 31, 2017, 2016 and 2015, products in our surgical pain, interventional pain, digestive health and respiratory health categories each accounted for more than 10% of our consolidated net sales. For the year ended December 31, 2017, 2016 and 2015, net sales to external customers in the United States were $467 million, $410 million and $389 million, respectively. Depreciation, amortization and capital expenditures are as follows (in millions):
| Year Ended December 31,
| 2017 |  | 2016 |  | 2015
Depreciation and Amortization |  |  |  |  |
Medical Devices | $ | 27.4 |  |  | $ | 30.4 |  |  | $ | 30.8 |
Corporate and Other(a) | 32.1 |  |  | 34.8 |  |  | 34.6 |
Total Depreciation and Amortization | 59.5 |  |  | 65.2 |  |  | 65.4 |
Capital Expenditures |  |  |  |  |
Medical Devices | $ | 21.9 |  |  | $ | 17.7 |  |  | $ | 23.2 |
Corporate and Other(b) | 21.3 |  |  | 11.4 |  |  | 47.2 |
Total Capital Expenditures | $ | 43.2 |  |  | $ | 29.1 |  |  | $ | 70.4 |
_______________________________________________
(a) | Depreciation and Amortization in Corporate and Other includes depreciation of corporate assets and depreciation and amortization of assets associated with discontinued operations (See “Discontinued Operations” in Note 2).
(b) | Corporate and other capital expenditures includes expenditures for corporate assets and expenditures associated with discontinued operations.
Information concerning assets by business segment is presented in the following table (in millions):
| As of December 31,
| 2017 |  | 2016
Assets |  |  |
Medical Devices | $ | 1,189.6 |  |  | $ | 1,197.2 |
Corporate and Other(a) | 1,006.3 |  |  | 874.6 |
Total Assets | $ | 2,195.9 |  |  | $ | 2,071.8 |
_______________________________________________
(a) | Corporate and other assets includes corporate assets, certain current assets and liabilities associated with discontinued operations that we will retain after closing the Divestiture and assets held for sale.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration